secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001104659-25-058379
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated
--------------------------------------------------------------------------------

- COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
- Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.
- Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.
- Novavax continues to pursue partnering opportunities to advance further development of these programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/0001104659-25-058379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/tm2517661d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-058379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer